4.2 Review

Early Intervention in Psychosis Obvious, Effective, Overdue

Journal

JOURNAL OF NERVOUS AND MENTAL DISEASE
Volume 203, Issue 5, Pages 310-318

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/NMD.0000000000000284

Keywords

Early intervention; psychosis; prevention; service reform

Funding

  1. Colonial Foundation
  2. National Health and Medical Research Council of Australia
  3. NARSAD
  4. Stanley Foundation
  5. Australian government
  6. Victorian government
  7. Janssen-Cilag
  8. Astra Zeneca
  9. Bristol-Meyer-Squibb
  10. Eli Lilly
  11. Pfizer

Ask authors/readers for more resources

Early intervention for potentially serious disorder is a fundamental feature of healthcare across the spectrum of physical illness. It has been a major factor in the reductions in morbidity and mortality that have been achieved in some of the non-communicable diseases, notably cancer and cardiovascular disease. Over the past two decades, an international collaborative effort has been mounted to build the evidence and the capacity for early intervention in the psychotic disorders, notably schizophrenia, where for so long deep pessimism had reigned. The origins and rapid development of early intervention in psychosis are described from a personal and Australian perspective. This uniquely evidence-informed, evidence-building and cost-effective reform provides a blueprint and launch pad to radically change the wider landscape of mental health care and dissolve many of the barriers that have constrained progress for so long.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available